ZIM LABORATORIES
|
ZIM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 3.54 | 5.01 | 8.96 | 4.51 | 2.04 |
| CEPS(Rs) | 6.81 | 8.60 | 6.28 | 4.74 | 3.65 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 49.00 | 41.12 | 108.18 | 98.97 | 94.84 |
| Tax Rate(%) | 27.05 | 30.89 | 30.85 | 28.48 | -4,705.54 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.25 | 13.04 | 12.29 | 12.94 | 8.14 |
| EBIT Margin(%) | 8.32 | 10.27 | 8.80 | 6.88 | 4.58 |
| Pre Tax Margin(%) | 6.43 | 8.87 | 6.31 | 3.33 | 0.02 |
| PAT Margin (%) | 4.69 | 6.13 | 4.36 | 2.38 | 1.19 |
| Cash Profit Margin (%) | 9.04 | 10.51 | 9.17 | 7.52 | 6.38 |
| Performance Ratios | |||||
| ROA(%) | 4.38 | 7.14 | 4.37 | 2.28 | 1.02 |
| ROE(%) | 7.86 | 13.00 | 8.65 | 4.66 | 2.17 |
| ROCE(%) | 10.11 | 16.82 | 12.52 | 8.70 | 5.39 |
| Asset Turnover(x) | 0.93 | 1.16 | 1.00 | 0.96 | 0.86 |
| Sales/Fixed Asset(x) | 1.58 | 2.10 | 1.93 | 1.89 | 1.88 |
| Working Capital/Sales(x) | 5.39 | 4.97 | 5.03 | 6.18 | 7.20 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.63 | 0.48 | 0.52 | 0.53 | 0.53 |
| Receivable days | 97.06 | 84.61 | 88.55 | 83.26 | 105.81 |
| Inventory Days | 67.04 | 59.07 | 70.95 | 65.77 | 73.23 |
| Payable days | 128.40 | 127.86 | 166.10 | 150.56 | 175.89 |
| Valuation Parameters | |||||
| PER(x) | 26.98 | 14.44 | 5.95 | 5.36 | 9.15 |
| PCE(x) | 14.02 | 8.42 | 8.49 | 5.10 | 5.11 |
| Price/Book(x) | 1.95 | 1.76 | 1.48 | 0.73 | 0.59 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.53 | 1.02 | 0.92 | 0.62 | 0.64 |
| EV/Core EBITDA(x) | 12.06 | 6.93 | 6.74 | 4.52 | 6.50 |
| EV/EBIT(x) | 18.36 | 9.89 | 10.42 | 9.01 | 13.87 |
| EV/CE(x) | 1.63 | 1.56 | 1.35 | 0.79 | 0.72 |
| M Cap / Sales | 1.27 | 0.89 | 0.78 | 0.38 | 0.33 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -7.80 | 19.52 | 8.52 | 10.63 | -17.18 |
| Core EBITDA Growth(%) | -20.34 | 28.68 | 7.80 | 55.15 | -38.44 |
| EBIT Growth(%) | -25.32 | 39.46 | 38.90 | 66.07 | -61.05 |
| PAT Growth(%) | -29.42 | 67.93 | 98.84 | 121.97 | -78.51 |
| EPS Growth(%) | -29.42 | -44.02 | 98.85 | 121.13 | -78.59 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.44 | 0.30 | 0.29 | 0.50 | 0.59 |
| Current Ratio(x) | 1.43 | 1.72 | 1.45 | 1.35 | 1.27 |
| Quick Ratio(x) | 0.92 | 1.24 | 0.94 | 0.97 | 0.88 |
| Interest Cover(x) | 4.41 | 7.34 | 3.53 | 1.94 | 1.01 |
| Total Debt/Mcap(x) | 0.23 | 0.17 | 0.20 | 0.69 | 0.99 |
Compare Financial Ratios of peers of ZIM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ZIM LABORATORIES | ₹522.1 Cr | -1.7% | -2.3% | -4.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,603.0 Cr | 3.7% | 8.5% | 49.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹160,862.0 Cr | 3.6% | 1.8% | 52.1% | Stock Analytics | |
| CIPLA | ₹122,810.0 Cr | 3% | 1.9% | 20.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,946.0 Cr | 2.7% | 15.5% | 23.2% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,377.1 Cr | -1.6% | 1% | 43.9% | Stock Analytics | |
ZIM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZIM LABORATORIES | -1.7% |
-2.3% |
-4.4% |
| SENSEX | 0.3% |
-2.5% |
10% |
You may also like the below Video Courses
